Compare
Black Hawk Acquisition Corp vs Pluri Inc. vs Atara Biotherapeutics, Inc. vs Curis Inc
| Latest fiscal year | Black Hawk Acquisition Corp BKHA | Pluri Inc. PLUR | Atara Biotherapeutics, Inc. ATRA | Curis Inc CRIS |
|---|---|---|---|---|
| Year ended | 2025-11-30 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.02M | $120.77M | $9.44M |
| Revenue growth (YoY) | n/a | -24.0% | -6.3% | -13.4% |
| Gross margin | n/a | 44.6% | n/a | n/a |
| Operating margin | n/a | n/m | 29.7% | -60.5% |
| Net margin | n/a | n/m | 27.1% | -80.3% |
| Net income | $1.33M | -$23.82M | $32.69M | -$7.58M |
| EPS (Diluted) | n/a | -$2.44 | $2.57 | -$0.58 |
| Operating cash flow | -$650.3K | -$19.59M | -$50.94M | -$27.20M |
| Free cash flow | n/a | -$20.22M | -$50.94M | n/a |
| Cash & equivalents | $0 | $3.53M | $8.48M | $5.06M |
| Total assets | $23.88M | $24.88M | $20.23M | $19.97M |
| Total liabilities | $3.90M | n/a | $58.74M | $14.50M |
| Shareholders' equity | -$3.85M | -$23.04M | -$38.50M | $5.46M |
| Return on year-end equity | n/a | n/a | n/a | -138.8% |
| Shares outstanding | n/a | 10.82M | 7.32M | 12.93M |
Revenue, most recent five fiscal years
| Fiscal year | Black Hawk Acquisition Corp | Pluri Inc. | Atara Biotherapeutics, Inc. | Curis Inc |
|---|---|---|---|---|
| Latest | n/a | $1.02M Ended 2026-06-30 | $120.77M Ended 2025-12-31 | $9.44M Ended 2025-12-31 |
| 1 year earlier | n/a | $1.34M Ended 2025-06-30 | $128.94M Ended 2024-12-31 | $10.91M Ended 2024-12-31 |
| 2 years earlier | n/a | $326.0K Ended 2024-06-30 | $8.57M Ended 2023-12-31 | $10.02M Ended 2023-12-31 |
| 3 years earlier | n/a | $287.0K Ended 2023-06-30 | $63.57M Ended 2022-12-31 | $10.16M Ended 2022-12-31 |
| 4 years earlier | n/a | $234.0K Ended 2022-06-30 | n/a | $10.65M Ended 2021-12-31 |